BRISTOL-MYERS SQUIBB COMPANY Proceeds from (Payments for) Other Financing Activities
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Proceeds from (Payments for) Other Financing Activities of $27.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2024-02-13
- BRISTOL-MYERS SQUIBB COMPANY proceeds from (payments for) other financing activities for the quarter ending 2022-12-31 was $179.00M.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from (payments for) other financing activities for the quarter ending 2022-09-30 was $53.00M, a 72.96% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from (payments for) other financing activities for the quarter ending 2022-06-30 was $419.00M, a 51.81% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from (payments for) other financing activities for the quarter ending 2022-03-31 was $333.00M, a 93.60% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from (payments for) other financing activities for fiscal 2023 was $27.00M, a 97.26% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from (payments for) other financing activities for fiscal 2022 was $984.00M, a 53.51% increase from fiscal 2021.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from (payments for) other financing activities for fiscal 2021 was $641.00M, a 18.27% increase from fiscal 2020.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from (payments for) other financing activities for fiscal 2020 was $542.00M.
| Period end | Proceeds from (Payments for) Other Financing Activities 3 month | Proceeds from (Payments for) Other Financing Activities 6 month | Proceeds from (Payments for) Other Financing Activities 9 month | Proceeds from (Payments for) Other Financing Activities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $27.00M 10-K · filed 2024-02-13 | |||
| 2022-12-31 | $179.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $232.00M derived: sum of 2 quarters · filed 2024-02-13 | $651.00M derived: sum of 3 quarters · filed 2024-02-13 | $984.00M 10-K · filed 2024-02-13 |
| 2022-09-30 | $53.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $472.00M derived: sum of 2 quarters · filed 2022-10-26 | $805.00M 10-Q · filed 2022-10-26 | $802.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $419.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $752.00M 10-Q · filed 2022-07-27 | $749.00M derived: sum of 3 quarters · filed 2024-02-13 | $945.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $333.00M 10-Q · filed 2022-04-29 | $330.00M derived: sum of 2 quarters · filed 2024-02-13 | $526.00M derived: sum of 3 quarters · filed 2024-02-13 | $802.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | -$3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $193.00M derived: sum of 2 quarters · filed 2024-02-13 | $469.00M derived: sum of 3 quarters · filed 2024-02-13 | $641.00M 10-K · filed 2024-02-13 |
| 2021-09-30 | $196.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $472.00M derived: sum of 2 quarters · filed 2022-10-26 | $644.00M 10-Q · filed 2022-10-26 | $921.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $276.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $448.00M 10-Q · filed 2022-07-27 | $725.00M derived: sum of 3 quarters · filed 2023-02-14 | $896.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $172.00M 10-Q · filed 2022-04-29 | $449.00M derived: sum of 2 quarters · filed 2023-02-14 | $620.00M derived: sum of 3 quarters · filed 2023-02-14 | $696.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $277.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $448.00M derived: sum of 2 quarters · filed 2023-02-14 | $524.00M derived: sum of 3 quarters · filed 2023-02-14 | $542.00M 10-K · filed 2023-02-14 |
| 2020-09-30 | $171.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $247.00M derived: sum of 2 quarters · filed 2021-10-27 | $265.00M 10-Q · filed 2021-10-27 | $252.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | $76.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $94.00M 10-Q · filed 2021-07-28 | $81.00M derived: sum of 3 quarters · filed 2022-02-09 | $80.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | $18.00M 10-Q · filed 2021-04-29 | $5.00M derived: sum of 2 quarters · filed 2022-02-09 | $4.00M derived: sum of 3 quarters · filed 2022-02-09 | $2.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2019-12-31 | -$13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | -$14.00M derived: sum of 2 quarters · filed 2022-02-09 | -$16.00M derived: sum of 3 quarters · filed 2022-02-09 | -$53.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$3.00M derived: sum of 2 quarters · filed 2020-11-05 | -$40.00M 10-Q · filed 2020-11-05 | -$39.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$39.00M 10-Q · filed 2020-08-06 | -$38.00M derived: sum of 3 quarters · filed 2021-02-10 | -$34.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | -$37.00M 10-Q · filed 2020-05-07 | -$36.00M derived: sum of 2 quarters · filed 2021-02-10 | -$32.00M derived: sum of 3 quarters · filed 2021-02-10 | -$33.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $5.00M derived: sum of 2 quarters · filed 2021-02-10 | $4.00M derived: sum of 3 quarters · filed 2021-02-10 | -$54.00M 10-K · filed 2021-02-10 |
| 2018-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $3.00M derived: sum of 2 quarters · filed 2019-10-31 | -$55.00M 10-Q · filed 2019-10-31 | -$48.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | -$1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | -$59.00M 10-Q · filed 2019-07-25 | -$52.00M derived: sum of 3 quarters · filed 2020-02-24 | -$46.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | -$58.00M 10-Q · filed 2019-04-25 | -$51.00M derived: sum of 2 quarters · filed 2020-02-24 | -$45.00M derived: sum of 3 quarters · filed 2020-02-24 | -$42.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $13.00M derived: sum of 2 quarters · filed 2020-02-24 | $16.00M derived: sum of 3 quarters · filed 2020-02-24 | -$22.00M 10-K · filed 2020-02-24 |
| 2017-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $9.00M derived: sum of 2 quarters · filed 2018-10-25 | -$29.00M 10-Q · filed 2018-10-25 | -$7.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | -$35.00M 10-Q · filed 2018-07-26 | -$13.00M derived: sum of 3 quarters · filed 2019-02-25 | -$8.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | -$38.00M 10-Q · filed 2018-04-26 | -$16.00M derived: sum of 2 quarters · filed 2019-02-25 | -$11.00M derived: sum of 3 quarters · filed 2019-02-25 | $22.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $27.00M derived: sum of 2 quarters · filed 2019-02-25 | $60.00M derived: sum of 3 quarters · filed 2019-02-25 | $15.00M 10-K · filed 2019-02-25 |
| 2016-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $38.00M derived: sum of 2 quarters · filed 2017-10-26 | -$7.00M 10-Q · filed 2017-10-26 | |
| 2016-06-30 | $33.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | -$12.00M 10-Q · filed 2017-07-27 | ||
| 2016-03-31 | -$45.00M 10-Q · filed 2017-04-27 | |||
| 2015-12-31 | -$9.00M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |